BioCryst Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 6,158 call options on the company. This is an increase of approximately 593% compared to the average volume of 888 call options.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,322 shares in the last quarter. Captrust Financial Advisors boosted its stake in shares of BioCryst Pharmaceuticals by 19.4% during the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company's stock valued at $124,000 after acquiring an additional 2,644 shares during the last quarter. Creative Planning increased its position in BioCryst Pharmaceuticals by 5.9% during the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company's stock worth $375,000 after purchasing an additional 2,734 shares in the last quarter. SkyView Investment Advisors LLC increased its position in BioCryst Pharmaceuticals by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company's stock valued at $429,000 after purchasing an additional 3,518 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

BCRX traded down $0.01 during midday trading on Friday, reaching $8.72. 2,340,286 shares of the company's stock were exchanged, compared to its average volume of 2,553,611. The business's 50-day moving average price is $7.72 and its 200 day moving average price is $7.72. The stock has a market capitalization of $1.81 billion, a PE ratio of -14.29 and a beta of 1.75. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $9.00.

Analyst Upgrades and Downgrades

A number of research firms have commented on BCRX. JMP Securities reissued a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC upped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. Barclays increased their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Finally, Evercore ISI boosted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.